title: Expression of beta-globin in primary erythroid progenitors of beta-thalassemia patients using an SV40-based gene delivery system.
abstract: SV40-based vectors are very efficient in gene delivery into human hematopoietic cells. In the present work, we investigated the expression of constructs carrying the human beta-globin gene that were delivered as beta-globin pseudovirions. Expression studies were performed by RNA analysis of primary human erythroid progenitors cultivated from peripheral blood of beta(0)-thalassemia patients who are unable to produce normal beta-globin RNA. This erythroid culture system recapitulates in vitro the process of growth, differentiation, and maturation of authentic erythroid precursors. The progenitors were induced to differentiate by the addition of erythropoietin (EPO). Five days later, the cells were infected with pseudovirions containing the normal beta-globin gene, and RNA was harvested on day 8. The results showed significant levels of normal beta-globin gene mRNA. A small DNA fragment derived from the 5'-region of the HSII element of the human beta-globin locus control region (LCR) enhanced expression of the linked beta-globin gene 20-30-fold. Normal beta-globin mRNA expression was in direct correlation to the multiplicity of infection. These studies suggest the potential feasibility of using the beta-globin delivery system for gene therapy of beta-thalassemia.
authors.affiliation: Department of Hematology, Hebrew University-Hadassah Medical School and Hadassah University Hospital, Jerusalem, Israel.
authors.forename: N
authors.initials: N
authors.lastname: Dalyot-Herman
authors.forename: D
authors.initials: D
authors.lastname: Rund
authors.forename: A
authors.initials: A
authors.lastname: Oppenheim
mesh_terms: D002454:Cell Differentiation / Q000187:drug effects / Q000235:genetics; D002478:Cells, Cultured; D015672:Erythroid Precursor Cells / Q000378:metabolism* / Q000821:virology; D004920:Erythropoiesis / Q000235:genetics*; D004921:Erythropoietin / Q000494:pharmacology; D005240:Feasibility Studies; D018507:Gene Expression Regulation, Developmental; D015316:Genetic Therapy; D005822:Genetic Vectors / Q000235:genetics*; D005914:Globins / Q000096:biosynthesis / Q000235:genetics*; D006801:Humans; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D013539:Simian virus 40 / Q000235:genetics*; D017086:beta-Thalassemia / Q000235:genetics* / Q000473:pathology
chemical_list: D012333:RNA, Messenger; D004921:Erythropoietin; D005914:Globins